TORONTO—Canada’s protection of intellectual property (IP) for biologic medicines—used to treat cancer and other maladies—lags behind other countries, limiting access and stunting investment, finds a new study released todayby the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.
The study, The Biologics Revolution in the Production of Drugs, spotlights the emerging science of biologic medicines, which involve genetically engineering living cells to produce needed proteins. Biologics have shown great promise in the treatment, diagnosis and prevention of more than 250 diseases including a variety of cancers.
